Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion

Cancer Letters

Volumn 331, Issue 1, 2013, Pages 122-129

  Vijayaraghavalu, Sivakumar ^a   Labhasetwar, Vinod ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Cancer therapy; Cell cycle analysis; Drug delivery; Epigenetic drugs; Hypermethylation; Nanoparticles

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE 1; DOXORUBICIN; NANOGEL; NANOPARTICLE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MELANOMA CELL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN DEPLETION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; EPIGENOMICS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; TUMOR CELLS, CULTURED;

EID: 84873524480     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.12.009     Document Type: Article

References (41)

1. Mutze K., Langer R., Schumacher F., Becker K., Ott K., Novotny A., Hapfelmeier A., Hofler H., Keller G. DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer. Eur. J. Cancer 2011, 47:1817-1825.
2. Robert M.F., Morin S., Beaulieu N., Gauthier F., Chute I.C., Barsalou A., MacLeod A.R. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. 2003, 33:61-65.
3. Ting A.H., Jair K.W., Suzuki H., Yen R.W., Baylin S.B., Schuebel K.E. CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat. Genet. 2004, 36:582-584.
4. Clements E.G., Mohammad H.P., Leadem B.R., Easwaran H., Cai Y., Van Neste L., Baylin S.B. DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. Nucl. Acids Res. 2012, 40:4334-4346.
5. Teodoridis J.M., Strathdee G., Brown R. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist. Update 2004, 7:267-278.
6. Cheung H.H., Lee T.L., Rennert O.M., Chan W.Y. DNA methylation of cancer genome. Birth Def. Res. C. Embryo Today Rev. 2009, 87:335-350.
7. Wilting R.H., Dannenberg J.H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist. Update 2012, 15:21-38.
8. Dhe-Paganon S., Syeda F., Park L. DNA methyl transferase 1: regulatory mechanisms and implications in health and disease. Int. J. Biochem. Mol. Biol. 2011, 2:58-66.
9. Ren J., Singh B.N., Huang Q., Li Z., Gao Y., Mishra P., Hwa Y.L., Li J., Dowdy S.C., Jiang S.W. DNA hypermethylation as a chemotherapy target. Cell. Signal. 2011, 23:1082-1093.
10. Onda K., Suzuki R., Tanaka S., Oga H., Oka K., Hirano T. Decitabine, a DNA methyltransferase inhibitor, reduces P-glycoprotein mRNA and protein expressions and increases drug sensitivity in drug-resistant MOLT4 and jurkat cell lines. Anticancer Res. 2012, 32:4439-4444.
11. Daniel F.I., Cherubini K., Yurgel L.S., de Figueiredo M.A., Salum F.G. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer 2011, 117:677-687.
12. Goffin J., Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann. Oncol. 2002, 13:1699-1716.
13. Y. Boumber, J.P. Issa, Epigenetics in cancer: what's the future? Oncology (Williston Park) 25 (2011) 220-226, 228.
14. Haaf T. The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. Pharmacol. Ther. 1995, 65:19-46.
15. Covey J.M., Zaharko D.S. Effects of dose and duration of exposure on 5-aza-2'-deoxycytidine cytotoxicity for L1210 leukemia in vitro. Cancer Treat. Rep. 1984, 68:1475-1481.
16. Brown R., Plumb J.A. Demethylation of DNA by decitabine in cancer chemotherapy. Expert. Rev. Anticancer Ther. 2004, 4:501-510.
17. Gros C., Fahy J., Halby L., Dufau I., Erdmann A., Gregoire J.M., Ausseil F., Vispe S., Arimondo P.B. DNA methylation inhibitors in cancer: recent and future approaches. Biochimie 2012, 94:2280-2296.
18. Mund C., Hackanson B., Stresemann C., Lubbert M., Lyko F. Characterization of DNA demethylation effects induced by 5-aza-2'-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res. 2005, 65:7086-7090.
19. Chan C.K., Chu I.M. In vitro degradation of poly(sebacic anhydride-co-ethylene glycol). Mater. Chem. Phys. 2004, 88:59-66.
20. Taratina T.M., Potapenko V., Klenin S.I., Bartoshevich S.P., Volkova L.A., Denisov I.G., Moskvichev B.V. Study of the structure of streptokinase conjugates with a hydrophilic vinylpyrrolidone copolymer. Biophys. Chem. 1990, 38:1-10.
21. Abraham G.A., de Queiroz A.A., Roman J.S. Hydrophilic hybrid IPNs of segmented polyurethanes and copolymers of vinylpyrrolidone for applications in medicine. Biomaterials 2001, 22:1971-1985.
22. Yallapu M.M., Vasir J.K., Jain T.K., Vijayaraghavalu S., Labhasetwar V. Synthesis, characterization and antiproliferative activity of rapamycin-loaded poly(N-isopropylacrylamide)-based nanogels in vascular smooth muscle cells. J. Biomed. Nanotechnol. 2008, 4:16-24.
23. Zhu X., Yan C., Winnik F.M., Leckband D. End-grafted low-molecular-weight PNIPAM does not collapse above the LCST. Langmuir 2007, 23:162-169.
24. Ahmed Z., Gooding E.A., Pimenov K.V., Wang L., Asher S.A. UV resonance Raman determination of molecular mechanism of poly(N-isopropylacrylamide) volume phase transition. J. Phys. Chem. B 2009, 113:4248-4256.
25. Reddy M.K., Vasir J.K., Sahoo S.K., Jain T.K., Yallapu M.M., Labhasetwar V. Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery. Circ. Cardiovasc. Interv. 2008, 1:209-216.
26. Hubeek I., Stam R.W., Peters G.J., Broekhuizen R., Meijerink J.P., van Wering E.R., Gibson B.E., Creutzig U., Zwaan C.M., Cloos J., Kuik D.J., Pieters R., Kaspers G.J. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br. J. Cancer 2005, 93:1388-1394.
27. Damaraju V.L., Mowles D., Yao S., Ng A., Young J.D., Cass C.E., Tong Z. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides Nucleotides Nucl. Acids 2012, 31:236-255.
28. Jabbour E., Issa J.P., Garcia-Manero G., Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 2008, 112:2341-2351.
29. Daskalakis M., Blagitko-Dorfs N., Hackanson B. Decitabine. Recent Results Cancer Res. 2010, 184:131-157.
30. Oki Y., Aoki E., Issa J.P. Decitabine - bedside to bench. Crit. Rev. Oncol. Hematol. 2007, 61:140-152.
31. Jansen R.S., Rosing H., Wijermans P.W., Keizer R.J., Schellens J.H., Beijnen J.H. Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study. Cancer Chemother. Pharmacol. 2012, 69:1457-1466.
32. Vijayaraghavalu S., Dermawan K.T., Cheriyath V., Labhasetwar V. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol. Pharmaceutics 2013, 10:337-352.
33. Tan H.H., Porter A.G. P21(WAF1) negatively regulates DNMT1 expression in mammalian cells. Biochem. Biophys. Res. Commun. 2009, 382:171-176.
34. Blagosklonny M.V. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 2007, 6:70-74.
35. Cherblanc F., Chapman-Rothe N., Brown R., Fuchter M.J. Current limitations and future opportunities for epigenetic therapies. Future Med. Chem. 2012, 4:425-446.
36. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
37. Hollenbach P.W., Nguyen A.N., Brady H., Williams M., Ning Y., Richard N., Krushel L., Aukerman S.L., Heise C., MacBeth K.J. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 2010, 5:e9001.
38. Momparler R.L., Bouffard D.Y., Momparler L.F., Dionne J., Belanger K., Ayoub J. Pilot phase I-II study on 5-aza-2'-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997, 8:358-368.
39. Brunner N., Bronzert D., Vindelov L.L., Rygaard K., Spang-Thomsen M., Lippman M.E. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res. 1989, 49:1515-1520.
40. Terry N.H., Meistrich M.L., Roubein L.D., Lynch P.M., Dubrow R.A., Rich T.A. Cellular kinetics in rectal cancer. Br. J. Cancer 1995, 72:435-441.
41. Oloumi A., Maidan M., Lock F.E., Tearle H., McKinney S., Muller W.J., Aparicio S.A., Dedhar S. Cooperative signaling between Wnt1 and integrin-linked kinase induces accelerated breast tumor development. Breast Cancer Res. 2010, 12:R38.